Sinonasal Cancer
Nasal cavity cancer · Paranasal sinus cancer · Maxillary sinus cancer · Esthesioneuroblastoma | ICD-O-3 C30–C31
Sinonasal cancer is a rare group of tumours arising in the nasal cavity and paranasal sinuses, including squamous cell carcinoma, adenocarcinoma, melanoma, lymphoma and esthesioneuroblastoma. There is no strong endemic country, but well-defined occupational clusters occur in industrialised countries — especially wood-dust-associated ethmoid adenocarcinoma. Symptoms mimic chronic sinusitis, so diagnosis is often delayed.
Sinonasal malignancies account for only a few percent of head and neck cancers, but they are unusually heterogeneous: more than a dozen histological types occur in a small anatomical space. The maxillary sinus is the most frequently involved sinus; the ethmoid sinus is classically associated with wood-dust exposure. Because the sinuses are air-filled cavities, tumours can become large before producing signs.
The single most important diagnostic lesson is that unilateral, persistent nasal symptoms are not 'just sinusitis'. One-sided blockage, bleeding, loss of smell, facial numbness, double vision, a swollen cheek or palate, or a loose upper tooth should prompt nasal endoscopy and contrast imaging. Biopsy should be planned after imaging when a vascular tumour or skull-base lesion is possible.
Where in the world is sinonasal cancer common?
roughly 3–5% of all head and neck malignancies; incidence around 0.5–1 case per 100,000 per year in Western registries were estimated worldwide in 2022 (no single global ASR — sinonasal sites are grouped within C30–C31 and are too rare for stable country rankings).
Rarity plus varied coding means registry figures must be interpreted with caution; occupational cohort studies are more informative than national rankings.
| Region / country | What the data show |
|---|---|
| Europe (occupational clusters) | Wood-dust exposure in furniture, cabinet-making and sawmill workers is a recognised cause of ethmoid sinus adenocarcinoma, with well-documented occupational cohorts in France, Italy, Germany and the Nordic countries. |
| North America | Occupational nickel, chromium, formaldehyde and wood-dust exposures plus HPV-associated sinonasal squamous cell carcinoma are the main recognised risk patterns. |
| East Asia | Sinonasal undifferentiated carcinoma and EBV-associated sinonasal lymphoepithelial lesions are reported more often in EBV-endemic Asian populations, though all types remain rare. |
| North Africa & the Middle East | Nasopharyngeal carcinoma rather than sinonasal cancer dominates this region; distinguishing the two requires endoscopy and MRI because symptoms overlap. |
| No true endemic region | Unlike NPC or oral cavity cancer, sinonasal cancer shows no strong population-level geographic hotspot; exposure history matters more than nationality. |
What are the risk factors?
- Occupational wood dust (especially hardwood) — IARC Group 1 carcinogen for sinonasal adenocarcinoma
- Nickel compounds, hexavalent chromium, leather dust, formaldehyde and certain solvents
- Cigarette smoking and, for some histological types, high-risk HPV infection
- EBV in sinonasal lymphoepithelial carcinoma in endemic populations
- Inverted papilloma — a benign but locally aggressive tumour that can harbour or progress to squamous cell carcinoma
- Prior radiotherapy to the head and neck
What are the signs and symptoms?
- Persistent one-sided nasal obstruction or discharge that does not respond to treatment
- Recurrent unilateral nosebleeds or blood-stained discharge
- Reduced or lost sense of smell, facial pressure or a unilateral headache
- Facial numbness, cheek swelling, loose upper teeth or a palatal swelling
- Double vision, protruding eye (proptosis) or excessive tearing from orbital involvement
- A neck lump, or cranial nerve changes in advanced skull-base disease
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Nasal endoscopy with rigid or flexible scopes and photographic documentation
- Contrast MRI for soft tissue, perineural and skull-base extension; dedicated sinus CT for bone detail
- Image-planned biopsy (avoid blind biopsy of vascular lesions or encephaloceles) with expert head and neck pathology review
- Immunohistochemistry for HPV/p16, EBV (EBER), melanoma, lymphoma and neuroendocrine markers as indicated
- Neck imaging and PET-CT/chest imaging for high-grade or advanced disease; ophthalmology and neurosurgery input when the orbit or skull base is involved
- Multidisciplinary skull-base tumour board before any resection
Staging is site- and histology-specific (AJCC for nasal cavity/ethmoid and maxillary sinus; separate systems for esthesioneuroblastoma and mucosal melanoma). Extension to the orbit, skull base, cribriform plate, pterygoid region or dura usually indicates advanced T category and determines whether an endoscopic or open craniofacial resection is feasible.
What are the treatment options?
- Endoscopic endonasal skull-base resection for selected tumours, or craniofacial resection with orbital/skull-base reconstruction
- Postoperative radiotherapy (often IMRT or proton therapy) for most malignant and advanced tumours; concurrent chemoradiotherapy in selected histologies
- Neck dissection or nodal radiotherapy for node-positive squamous cell carcinoma, SNUC or melanoma
- Systemic therapy for sinonasal undifferentiated carcinoma, small-cell carcinoma, lymphoma and melanoma; immunotherapy for mucosal melanoma and PD-L1-positive squamous tumours
- Complete excision of inverted papilloma with surveillance for recurrence or malignant transformation
- Reconstruction, orbital/dural repair, olfactory and dental rehabilitation, and long-term endoscopic surveillance
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Outcome is driven more by histology and skull-base/orbital extension than by country. Localised, completely resected low-grade tumours can be controlled long-term, whereas sinonasal undifferentiated carcinoma, mucosal melanoma and tumours with dural or brain involvement have substantially poorer survival. Overall five-year survival across all types is commonly reported around 50–60% in mixed series.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Local exhaust ventilation, dust suppression and fitted respiratory protection in wood, leather, nickel and chromium work
- Smoking cessation and appropriate HPV vaccination according to national schedules
- Occupational health surveillance for exposed workers with persistent unilateral nasal symptoms
- Complete removal and long-term endoscopic follow-up of inverted papilloma
- Early nasal endoscopy for unilateral blockage, bleeding or smell loss lasting more than a few weeks
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
Chinese tertiary centres with endoscopic skull-base teams can offer image-guided sinonasal resection and reconstruction, plus IMRT and pathology review. Because these tumours are rare, international patients should verify the centre’s specific experience with their histological subtype and with proton therapy if skull-base dosing is a concern.
- Bring the biopsy slides for re-review (histology and HPV/EBV/melanoma markers), plus contrast MRI and dedicated sinus CT on DICOM.
- Ask whether the planned approach is purely endoscopic or combined craniofacial, and how the skull base and orbit would be reconstructed.
- Request a written radiotherapy plan specifying dose, technique (IMRT vs proton) and target volumes in English.
- Confirm drug availability if immunotherapy or targeted therapy is part of the plan; rare histologies often need agents that are not stocked everywhere.
Cost guidance: As an illustrative planning range, endoscopic resection is commonly budgeted at ¥50,000–¥130,000 (about US$7,000–18,000); combined craniofacial resection with reconstruction and adjuvant radiotherapy ¥130,000–¥280,000. Proton therapy and immunotherapy are priced separately. These are budgeting figures, not a quotation.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 13 questions about sinonasal cancer
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
4 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
3 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Prognosis & follow-up
1 questionSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
1 questionWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is sinonasal cancer?
Sinonasal cancer is a rare group of tumours arising in the nasal cavity and paranasal sinuses, including squamous cell carcinoma, adenocarcinoma, melanoma, lymphoma and esthesioneuroblastoma. There is no strong endemic country, but well-defined occupational clusters occur in industrialised countries — especially wood-dust-associated ethmoid adenocarcinoma. Symptoms mimic chronic sinusitis, so diagnosis is often delayed.
Where in the world is sinonasal cancer most common?
Sinonasal Cancer is not evenly distributed: the highest-burden regions are Europe (occupational clusters), North America and East Asia. In 2022 there were roughly 3–5% of all head and neck malignancies; incidence around 0.5–1 case per 100,000 per year in Western registries worldwide (no single global ASR — sinonasal sites are grouped within C30–C31 and are too rare for stable country rankings), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for sinonasal cancer?
The main recognised risk factors for sinonasal cancer are occupational wood dust (especially hardwood) — IARC Group 1 carcinogen for sinonasal adenocarcinoma, nickel compounds, hexavalent chromium, leather dust, formaldehyde and certain solvents and cigarette smoking and, for some histological types, high-risk HPV infection. Risks differ by region: Europe (occupational clusters) has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of sinonasal cancer?
The common early signs are persistent one-sided nasal obstruction or discharge that does not respond to treatment, recurrent unilateral nosebleeds or blood-stained discharge, reduced or lost sense of smell, facial pressure or a unilateral headache and facial numbness, cheek swelling, loose upper teeth or a palatal swelling. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is sinonasal cancer diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for sinonasal cancer?
Treatment is stage- and site-specific, and usually combines endoscopic endonasal skull-base resection for selected tumours, or craniofacial resection with orbital/skull-base reconstruction, postoperative radiotherapy (often IMRT or proton therapy) for most malignant and advanced tumours; concurrent chemoradiotherapy in selected histologies and neck dissection or nodal radiotherapy for node-positive squamous cell carcinoma, SNUC or melanoma. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for sinonasal cancer?
Outcome is driven more by histology and skull-base/orbital extension than by country. Localised, completely resected low-grade tumours can be controlled long-term, whereas sinonasal undifferentiated carcinoma, mucosal melanoma and tumours with dural or brain involvement have substantially poorer survival. Overall five-year survival across all types is commonly reported around 50–60% in mixed series.
Can sinonasal cancer be prevented?
Many cases are preventable. The most useful steps for sinonasal cancer are local exhaust ventilation, dust suppression and fitted respiratory protection in wood, leather, nickel and chromium work, smoking cessation and appropriate HPV vaccination according to national schedules and occupational health surveillance for exposed workers with persistent unilateral nasal symptoms. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
How can I tell sinusitis from sinonasal cancer?
You cannot reliably tell from symptoms alone. Sinusitis is usually bilateral, fluctuates and responds to treatment, whereas a tumour tends to cause persistent one-sided blockage, bleeding, smell loss, facial numbness, cheek or palate swelling, loose upper teeth or double vision. Any unilateral symptom lasting more than a few weeks warrants nasal endoscopy and imaging.
Is wood dust really a cause of sinus cancer?
Yes. Occupational exposure to hardwood dust is classified by IARC as a cause of sinonasal adenocarcinoma, particularly of the ethmoid sinuses, and is one of the clearest occupational links in head and neck oncology. Risk rises with duration and intensity of exposure, often with a latency of several decades.
What is an inverted papilloma and can it become cancer?
An inverted papilloma is a benign but locally aggressive sinonasal tumour that recurs if incompletely removed and is associated with squamous cell carcinoma in a minority of cases — either synchronous or at a later recurrence. Complete endoscopic excision of its attachment site and long-term surveillance are therefore standard.
Will surgery for a sinus tumour involve the brain or the eye?
Many sinonasal tumours can now be removed entirely through the nose using endoscopic skull-base surgery, without an external incision. Tumours involving the dura, brain, orbit or extensive facial soft tissue may still require a combined craniofacial approach with neurosurgery, ophthalmology and reconstructive flaps.
What does sinonasal cancer treatment cost in China?
Illustrative planning ranges are ¥50,000–¥130,000 (about US$7,000–18,000) for endoscopic resection and ¥130,000–¥280,000 for combined craniofacial resection with reconstruction and adjuvant radiotherapy. Proton therapy and immunotherapy are billed separately. These figures are not a quotation.
Sources for this topic
Ask about sinonasal cancer treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.